CN109689641A - 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 - Google Patents

一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN109689641A
CN109689641A CN201780055081.7A CN201780055081A CN109689641A CN 109689641 A CN109689641 A CN 109689641A CN 201780055081 A CN201780055081 A CN 201780055081A CN 109689641 A CN109689641 A CN 109689641A
Authority
CN
China
Prior art keywords
crystal form
compound
formula
crystal
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780055081.7A
Other languages
English (en)
Other versions
CN109689641B (zh
Inventor
丁照中
陈曙辉
胡利红
徐招兵
刘迎春
任兵杰
李卫东
李宗斌
赵锐
张喜全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN109689641A publication Critical patent/CN109689641A/zh
Application granted granted Critical
Publication of CN109689641B publication Critical patent/CN109689641B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种取代的2‑氢‑吡唑衍生物晶型、盐型及其制备方法，以及所述晶型和盐型在制备治疗乳腺癌、肺癌等癌症的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (34)

  1. PCT国内申请，权利要求书已公开。
CN201780055081.7A 2016-09-09 2017-09-08 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 Active CN109689641B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610814752 2016-09-09
CN2016108147520 2016-09-09
PCT/CN2017/101067 WO2018045993A1 (zh) 2016-09-09 2017-09-08 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN109689641A true CN109689641A (zh) 2019-04-26
CN109689641B CN109689641B (zh) 2020-11-03

Family

ID=61561674

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780055081.7A Active CN109689641B (zh) 2016-09-09 2017-09-08 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法

Country Status (5)

Country Link
US (1) US10626107B2 (zh)
EP (1) EP3502103B1 (zh)
JP (1) JP7100625B2 (zh)
CN (1) CN109689641B (zh)
WO (1) WO2018045993A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440401A (zh) * 2018-04-13 2018-08-24 华东理工大学 5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺的制备方法
US20220162185A1 (en) * 2019-03-20 2022-05-26 Beta Pharma, Inc. Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
CN113121424A (zh) * 2019-12-30 2021-07-16 浙江瑞博制药有限公司 连续化反应制备哌嗪吡啶化合物
CN115768763A (zh) 2020-06-22 2023-03-07 正大天晴药业集团股份有限公司 一种cdk4/6抑制剂的制备方法
WO2023237055A1 (zh) * 2022-06-09 2023-12-14 正大天晴药业集团股份有限公司 一种cdk4/6抑制剂治疗去分化脂肪肉瘤的用途
WO2024032751A1 (zh) * 2022-08-12 2024-02-15 正大天晴药业集团股份有限公司 一种取代的2-氢-吡唑衍生物的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264725B (zh) * 2008-12-22 2014-04-16 伊莱利利公司 蛋白激酶抑制剂
WO2015130540A1 (en) * 2014-02-26 2015-09-03 Eli Lilly And Company Combination therapy for cancer
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN105294655A (zh) * 2014-07-26 2016-02-03 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2806206T3 (es) * 2015-03-11 2021-02-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado de 2-hidrógeno pirazol sustituido que sirve como fármaco anticanceroso

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264725B (zh) * 2008-12-22 2014-04-16 伊莱利利公司 蛋白激酶抑制剂
WO2015130540A1 (en) * 2014-02-26 2015-09-03 Eli Lilly And Company Combination therapy for cancer
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN105294655A (zh) * 2014-07-26 2016-02-03 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Also Published As

Publication number Publication date
EP3502103B1 (en) 2022-04-06
WO2018045993A1 (zh) 2018-03-15
JP2019526605A (ja) 2019-09-19
US20190194168A1 (en) 2019-06-27
US10626107B2 (en) 2020-04-21
EP3502103A1 (en) 2019-06-26
JP7100625B2 (ja) 2022-07-13
CN109689641B (zh) 2020-11-03
EP3502103A4 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
CN109689641A (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
AU2013230146B2 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as Raf kinase inhibitors
CZ20022929A3 (cs) 5-Alkylpyrido[2,3-d]pyrimidinové inhibitory tyrosinových kinas
CN107137408A (zh) 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
CN108602815A (zh) 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
WO2021023272A1 (zh) 一种atr抑制剂的晶型及其应用
WO2023093861A1 (zh) Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
WO2022179577A1 (zh) 一种环丙基取代的苯并呋喃类化合物的晶型及其制备方法
CN110950847B (zh) 氘代azd9291化合物的新晶型及其用途
BR112020026052A2 (pt) forma de cristal do composto para a inibição da atividade de cdk4/6 e seu uso
WO2020147838A1 (zh) 一种egfr抑制剂的盐、晶型及其制备方法
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
TW202342463A (zh) Parp14抑制劑之固體形式
CN118076614A (zh) 一种egfr抑制剂的多晶型
TW202313034A (zh) Egfr抑制劑的鹽、晶型及其組合物和應用
CN115448874A (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
EP3971175A1 (en) Crystal form of quinazolinone compound and preparation method therefor
CN110128359B (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
EP3677581A1 (en) Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof
CN110054615A (zh) 三嗪类idh抑制剂甲磺酸盐的晶型
CN114644615B (zh) 一种吲唑类衍生物的结晶形式及其制备方法
WO2023093812A1 (zh) 三氮唑酮类化合物的晶型及其应用
WO2024153053A1 (zh) Cdk抑制剂及其可药用盐的晶型以及其用途
WO2023155841A1 (zh) 嘧啶并环类化合物的盐型、晶型
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant